CHIEF TECHNICAL OFFICER AND DIRECTOR
Robert Beecroft is the founder and Chief Technical Officer of ImmunoPrecise and previously served as its Chief Executive Officer and President. Mr. Beecroft has over 25 years’ experience in the development of innovative and proprietary methods for the production of monoclonal and polyclonal antibodies and peptides. Mr. Beecroft has a B.Sc. in Microbiology from University of Victoria and has been involved in over 15 Research Projects over the course of the last 25 years and been an instructor for graduate students at the University of Victoria on the use and production of monoclonal antibodies for over 13 years. In 2015, Mr. Beecroft was the recipient of the UVic Distinguished Alumni Award for the Faculty of Science, in recognition for being the Founder of ImmunoPrecise Antibodies Ltd.
James Kuo, MD, MBA
Dr. James Kuo brings considerable global life science business experience to ImmunoPrecise. Currently, he serves as Chief Executive Officer of the Finnish biotechnology company, FIT Biotech. He has also been Chairman and Chief Executive Officer of Synthetic Biologics and BioMicro Systems and Chief Executive Officer of Discovery Laboratories. In addition to these senior biotech leadership roles, Dr. Kuo has been head of business development at Myriad Genetics and Associate Director of Corporate Licensing and Development at Pfizer. He has further served as Managing Director of HealthCare Ventures, a $378 million venture capital fund, and is presently Managing Director at Athena Bioventures in La Jolla, CA. He is also a founder and Chairman of Monarch Labs. Dr. Kuo received his MD from the University of Pennsylvania School of Medicine and his MBA from the Wharton School of Business. He received his BA in molecular biology from Haverford College.
Guy Champagne is an accomplished businessman and entrepreneur. Director of Seahawk Ventures (CNSX:SHX) since August 2015. From January, 2014, actively involved involving the management and operation of a group of 5 privately-owned companies including: President of Aequitor Inc., Vice-President of Real Estate Webmasters Inc., executive team member of ImmunoPrecise Antibodies Ltd., Hardy Buoys Smoked Fish Inc., and Atlas Engineered Wood Products Inc. Served as Managing Partner and Senior Partner of BDC Consulting between 2006 and 2013, retiring in December 2013. From 1974 to 2005, served as founder, executive, investor and consultant with numerous privately-held technology companies until their sale and disposition in 2005 to pursue retirement. Maintained designation as a Certified Management Consultant (Canadian Association of Certified Management Consultants) until 2016. During the late 1970’s and 1980’s and coincident with early success in business, pursued education including the Canadian Securities Course, the Canadian Institute of Chartered Business Valuators training program for the Chartered Business Valuator designation, and Honours Mathematics at McGill University.
Greg Smith is a seasoned capital markets veteran who held senior positions in investment banking before recently transitioning to private equity with the acquisition of one of the largest HVAC companies in Western Canada. Mr. Smith also held the position of Portfolio Manager for Phillips, Hagar & North & Executive Director, Canadian Securitization Group, CIBC World Markets in Toronto for close to ten years. Mr. Smith, currently serves as President & Director of Broadway Refrigeration & Air Conditioning Co. Ltd. and Omega Mechanical Ltd. who collectively have over 150 employees. Mr. Smith earned an MBA from Dalhousie University and is a Chartered Financial Analyst and has served in advisory positions to multiple private and public ventures. He is currently serving as Chairman of Lite Access Technologies (TSXV:LTE).
Dr. Robert D. Burke
Dr. Robert D. Burke is an Emeritus Professor at the University of Victoria, where he was a faculty member for over 35 years. He has a longstanding research interest in the molecular basis of cellular signaling in early embryonic development. His research involves production and characterization of antibodies and he employs them extensively with high-resolution optical imaging methods. Dr. Burke has published over 100 peer-reviewed publications and has supervised numerous trainees. He was Chair of the Department of Biochemistry and Microbiology for 8 years, was on the University of Victoria Senate for 12 years, and served on numerous advisory and management committees nationally and internationally. Dr. Burke completed a BSc (Honours) and a PhD at the University of Alberta.